BlueCrest Capital Management’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
BlueCrest Capital Management's MLYS Position: Q3 2026 in Review
BlueCrest Capital Management sold out of Mineralys Therapeutics (MLYS) in Q3 2026, closing a stake of 85,157 shares — an estimated $2.3M sold.
BlueCrest Capital Management first reported a position in MLYS in Q2 2026 and held it in 1 quarter. The position peaked at $2.3M in Q2 2026. 217 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- BlueCrest Capital Management reported no remaining Mineralys Therapeutics position as of Q3 2026 after selling out during the quarter.
- BlueCrest Capital Management sold 85,157 Mineralys Therapeutics shares in Q3 2026, an estimated $2.3M.
- BlueCrest Capital Management first reported a position in Mineralys Therapeutics in Q2 2026 and held it in 1 quarter.
- BlueCrest Capital Management's Mineralys Therapeutics position peaked at $2.3M in Q2 2026.
- 217 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on BlueCrest Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.